Sugi Predict

Sugi Predict / Compounds / SCHEMBL166951

SCHEMBL166951

SCHEMBL166951

[2H]C([2H])(c1ccnc(N)c1)n1ccc2c(NC(=O)Nc3cc(Br)ccc3F)cccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 4/20 0.36
▸ FGFR4 P22455 4/20 0.36
▸ POLB P06746 1/20 0.35
▸ KDR P35968 3/20 0.34
▸ LCK P06239 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ KIT P10721 1/20 0.34
▸ FLT1 P17948 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ RIPK1 Q13546 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ EPHB4 P54760 2/20 0.34
▸ TEK Q02763 2/20 0.34
▸ ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165718 0.90 FGFR1 (0.40) FGFR1FGFR4KDRLCKCSF1R
SCHEMBL164013 0.90 RAB9A (0.40) POLBMEN1MAPTKMT2AROCK1
SCHEMBL168470 0.90 KDR (0.45) FGFR1KDRLCKCSF1RKIT
SCHEMBL168209 0.89 KDR (0.37) KDRKITFLT1FLT4FPR2
SCHEMBL167970 0.88 RIPK1 (0.47) KDRLCKCSF1RKITFLT1
SCHEMBL167218 0.88 TRPV1 (0.42) FGFR1KDRLCKCSF1RKIT
SCHEMBL168256 0.87 ROCK1 (0.44) FGFR1KDRFLT1FLT3MEN1
Ji-101 SCHEMBL165822 0.87 EPHB4 (0.44) KDRMEN1MAPTHTTKMT2A
SCHEMBL167600 0.87 EPHB4 (0.39) KITMEN1MAPTHTTKMT2A
SCHEMBL166661 0.86 ROCK1 (0.40) FGFR1FGFR4KDRLCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 — — EP claimed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 — — US claimed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 — — WO claimed
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 — — EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 — — US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 FGFR1 956/4885FGFR4 1668/4885POLB 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.